Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2

被引：6
|
作者：
Piccart, M. [1 ]
Hortobagyi, G. N. [2 ]
Campone, M. [3 ]
Pritchard, K. I. [4 ,5 ]
Noguchi, S. [6 ]
Rugo, H. [7 ]
Gnant, M. [8 ]
Feng, W. [7 ,9 ]
Taran, T. [9 ]
Baselga, J. [10 ]
机构：
[1] Inst Jules Bordet, B-1000 Brussels, Belgium
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Ctr Rech Canc, Inst Canc Ouest Rene Gauducheau, St Herblain, France
[4] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Osaka Univ, Sch Med, Suita, Osaka 565, Japan
[7] Univ Calif San Francisco, San Francisco, CA 94143 USA
[8] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria
[9] Novartis Oncol, E Hanover, NJ USA
[10] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)00221-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1LBA
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [1] Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Lebrun, F.
    Ito, Y.
    Noguchi, S.
    Perez, A.
    Rugo, H. S.
    Deleu, I.
    Burris, H. A., III
    Provencher, L.
    Neven, P.
    Gnant, M.
    Shtivelband, M.
    Wu, C.
    Fan, J.
    Feng, W.
    Taran, T.
    Baselga, J.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (12) : 2357 - 2362
  • [2] Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2
    Beck, J. Thaddeus
    Hortobagyi, Gabriel N.
    Campone, Mario
    Lebrun, Fabienne
    Deleu, Ines
    Rugo, Hope S.
    Pistilli, Barbara
    Masuda, Norikazu
    Hart, Lowell
    Melichar, Bohuslav
    Dakhil, Shaker
    Geberth, Matthias
    Nunzi, Martina
    Heng, Daniel Y. C.
    Brechenmacher, Thomas
    El-Hashimy, Mona
    Douma, Shyanne
    Ringeisen, Francois
    Piccart, Martine
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (03) : 459 - 467
  • [3] Patients' preferences for postmenopausal hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer treatments in Japan
    Omori, Y.
    Enatsu, S.
    Cai, Z.
    Ishiguro, H.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [4] Patterns of disease management for European postmenopausal women with hormone-receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer
    Marinsek, N.
    Andre, F.
    Neven, P.
    Zhang, J.
    Degun, R.
    Benelli, G.
    Saletan, S.
    Jerusalem, G.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S411 - S411
  • [5] Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2
    Prat, Aleix
    Christoph Brase, Jan
    Cheng, Yuan
    Nuciforo, Paolo
    Pare, Laia
    Pascual, Tomas
    Martinez, Debora
    Galvan, Patricia
    Vidal, Maria
    Adamo, Barbara
    Hortobagyi, Gabriel N.
    Baselga, Jose
    Ciruelos, Eva
    [J]. ONCOLOGIST, 2019, 24 (07): : 893 - 900
  • [6] Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2
    Hortobagyi, Gabriel N.
    Chen, David
    Piccart, Martine
    Rugo, Hope S.
    Burris, Howard A., III
    Pritchard, Kathleen I.
    Campone, Mario
    Noguchi, Shinzaburo
    Perez, Alejandra T.
    Deleu, Ines
    Shtivelband, Mikhail
    Masuda, Norikazu
    Dakhil, Shaker
    Anderson, Ian
    Robinson, Douglas M.
    He, Wei
    Garg, Abhishek
    McDonald, E. Robert, III
    Bitter, Hans
    Huang, Alan
    Taran, Tetiana
    Bachelot, Thomas
    Lebrun, Fabienne
    Lebwohl, David
    Baselga, Jose
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (05) : 419 - U79
  • [7] Hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer: Sequencing of chemotherapy and endocrine therapy
    Engel-Nitz, Nicole M.
    Hao, Yanni
    Rogerio, Jaqueline Willemann
    Turnbull, James D.
    Rey, Gabriel Gomez
    Sullivan, Jane
    Rossof, Arthur H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [8] Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3
    Cristofanilli, M.
    Slamon, D. J.
    Ro, J.
    Bondarenko, I.
    Im, S-A.
    Masuda, N.
    Colleoni, M.
    DeMichele, A.
    Loi, S.
    Verma, S.
    Iwata, H.
    Harbeck, N.
    Loibl, S.
    Andre, F.
    Theall, K. Puyana
    Huang, X.
    Giorgetti, C.
    Bartlett, C. Huang
    Turner, N. C.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [9] BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer.
    Noguchi, Shinzaburo
    Masuda, Norikazu
    Ito, Yoshinori
    Iwata, Hiroji
    Mukai, Hirofumi
    Horiguchi, Jun
    Tokuda, Yutaka
    Kuroi, Katsumasa
    Iwase, Hirotaka
    Inaji, Hideo
    Ohsumi, Shozo
    Piccart-Gebhart, Martine J.
    Hortobagyi, Gabriel N.
    Rugo, Hope S.
    Gnant, Michael
    Campone, Mario
    Sahmoud, Tarek
    Pritchard, Kathleen I.
    Burris, Howard A.
    Baselga, Jose
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] PAM50 intrinsic subtype in hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial
    Prat, A.
    Brase, J. C.
    Cheng, Y.
    Nuciforo, P.
    Pare, L.
    Pascual, T.
    Martinez, D.
    Galvan, P.
    Vidal, M.
    Adamo, B.
    Hortobagyi, G.
    Baselga, J.
    Ciruelos, E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 92 : S117 - S117
12345